EVGEN PHARMA PLC LS-0025
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and n… Read more
Market Cap & Net Worth: EVGEN PHARMA PLC LS-0025 (8EV)
EVGEN PHARMA PLC LS-0025 (F:8EV) has a market capitalization of $1.10 Million (€1.07 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #36973 globally and #4656 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying EVGEN PHARMA PLC LS-0025's stock price €0.00 by its total outstanding shares 2148963739 (2.15 Billion).
EVGEN PHARMA PLC LS-0025 Market Cap History: 2018 to 2026
EVGEN PHARMA PLC LS-0025's market capitalization history from 2018 to 2026. Data shows change from $383.60 Million to $1.10 Million (-53.85% CAGR).
EVGEN PHARMA PLC LS-0025 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how EVGEN PHARMA PLC LS-0025's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8EV by Market Capitalization
Companies near EVGEN PHARMA PLC LS-0025 in the global market cap rankings as of March 18, 2026.
Key companies related to EVGEN PHARMA PLC LS-0025 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
EVGEN PHARMA PLC LS-0025 Historical Marketcap From 2018 to 2026
Between 2018 and today, EVGEN PHARMA PLC LS-0025's market cap moved from $383.60 Million to $ 1.10 Million, with a yearly change of -53.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.10 Million | 0.00% |
| 2025 | €1.10 Million | 0.00% |
| 2024 | €1.10 Million | -80.00% |
| 2023 | €5.51 Million | -92.86% |
| 2022 | €77.20 Million | -23.91% |
| 2021 | €101.47 Million | -57.80% |
| 2020 | €240.44 Million | +62.69% |
| 2019 | €147.79 Million | -61.47% |
| 2018 | €383.60 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of EVGEN PHARMA PLC LS-0025 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.10 Million USD |
| MoneyControl | $1.10 Million USD |
| MarketWatch | $1.10 Million USD |
| marketcap.company | $1.10 Million USD |
| Reuters | $1.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.